BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $107.00

BridgeBio Pharma (NASDAQ:BBIO) had its price target lifted by equities research analysts at Truist Financial from $102.00 to $107.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price objective would suggest a potential upside of 27.14% from the company’s current price.

Several other research firms have also recently issued reports on BBIO. Piper Sandler increased their price objective on BridgeBio Pharma from $111.00 to $115.00 and gave the stock an “overweight” rating in a research report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $110.00 price target on shares of BridgeBio Pharma in a research note on Tuesday. Canaccord Genuity Group raised their price objective on shares of BridgeBio Pharma from $104.00 to $106.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup boosted their price objective on shares of BridgeBio Pharma from $82.00 to $93.00 and gave the stock a “neutral” rating in a report on Thursday, July 16th. Finally, Wells Fargo & Company upped their target price on shares of BridgeBio Pharma from $98.00 to $102.00 and gave the stock an “overweight” rating in a research report on Tuesday. Twenty equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $100.79.

BridgeBio Pharma Stock Performance

BBIO traded up $0.46 during trading on Wednesday, reaching $84.16. The company’s stock had a trading volume of 667,871 shares, compared to its average volume of 2,989,727. BridgeBio Pharma has a 52-week low of $46.81 and a 52-week high of $93.42. The company’s fifty day moving average price is $76.47 and its 200-day moving average price is $73.07. The company has a market capitalization of $16.45 billion, a price-to-earnings ratio of -23.57 and a beta of 0.96.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Monday, August 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The firm had revenue of $243.68 million during the quarter, compared to analyst estimates of $220.91 million. The company’s quarterly revenue was up 120.4% on a year-over-year basis. During the same period last year, the business posted ($0.95) earnings per share. Equities analysts predict that BridgeBio Pharma will post -2.31 earnings per share for the current year.

Insider Activity

In other news, CEO Neil Kumar sold 40,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $67.46, for a total value of $2,698,400.00. Following the sale, the chief executive officer directly owned 535,686 shares in the company, valued at $36,137,377.56. This represents a 6.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Thomas Trimarchi sold 13,651 shares of BridgeBio Pharma stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $65.08, for a total value of $888,407.08. Following the transaction, the chief financial officer owned 359,194 shares of the company’s stock, valued at $23,376,345.52. This represents a 3.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 392,117 shares of company stock worth $29,934,700 in the last three months. Company insiders own 14.23% of the company’s stock.

Hedge Funds Weigh In On BridgeBio Pharma

Several hedge funds have recently bought and sold shares of BBIO. EP Wealth Advisors LLC purchased a new stake in shares of BridgeBio Pharma in the second quarter valued at $529,000. Allworth Financial LP purchased a new stake in BridgeBio Pharma during the 2nd quarter worth about $31,000. B. Metzler seel. Sohn & Co. AG acquired a new position in BridgeBio Pharma in the 2nd quarter valued at about $1,304,000. Silvant Capital Management LLC acquired a new position in BridgeBio Pharma in the 2nd quarter valued at about $28,000. Finally, E Fund Management Co. Ltd. purchased a new position in BridgeBio Pharma in the 2nd quarter valued at about $452,000. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Key Stories Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Analyst sentiment strengthened broadly: JPMorgan raised its target to $111 and maintained an “overweight” rating; Canaccord Genuity lifted its target to $106 with a “buy” rating; and TD Cowen, Piper Sandler, Wells Fargo and Bank of America also increased their targets, generally citing improving commercial execution and pipeline potential. Benzinga analyst price-target updates
• Positive Sentiment: Attruby sales surged during the second quarter, with U.S. net sales reportedly increasing 311% year over year. Ex-U.S. Beyonttra royalties also rose 62% sequentially, supporting management’s reaffirmed goal of more than $1 billion in 2026 global Attruby and Beyonttra sales. BridgeBio: Attruby Delivers In Q2
• Positive Sentiment: Revenue reached $243.7 million, beating the $220.9 million consensus estimate and increasing 120.4% year over year. BridgeBio also highlighted expectations for three product launches by mid-2027, adding potential catalysts for the stock. BridgeBio Q2 Earnings Miss, Revenues Beat
• Positive Sentiment: A $1 billion preferred-equity raise is expected to improve BridgeBio’s financial flexibility and help fund commercial expansion and pipeline development.
• Neutral Sentiment: BridgeBio granted restricted stock units covering 66,705 shares to 56 new employees. The grants may help retain talent but create limited potential share dilution. BridgeBio Inducement Grants
• Negative Sentiment: Second-quarter adjusted results were weaker than expected: BridgeBio reported a loss of $0.78 per share versus the $0.58 consensus estimate, despite the substantial revenue beat.
• Negative Sentiment: Morgan Stanley trimmed its price target to $97 from $98, though it retained an “overweight” rating, signaling some caution regarding valuation or execution risks. Benzinga analyst update

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.